Dupilumab as a combination therapy to oral systemic immunomodulators for moderate-to-severe atopic dermatitis for skin of color children in resource-limited setting: A case series
Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poo...
Saved in:
Main Authors: | Siti Nuraihan (Author), M N Azmi (Author), Sabeera Begum (Author), Kin Fon Leong (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Individualized dupilumab therapy in the treatment of pediatric patients with severe atopic dermatitis: Case series in a Malaysian Tertiary Center
by: Wai Quen Lee, et al.
Published: (2022) -
Early-onset, severe prurigo nodularis in a young child with atopic dermatitis treated successfully with dupilumab
by: Henrietta Albela, et al.
Published: (2022) -
Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023) -
Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
by: Adrien Mareschal, et al.
Published: (2020) -
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)